Ser460
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser460  -  EPB41L3 (human)

Site Information
yATTKGIsQtNLITt   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 454222

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 )
Disease tissue studied:
bone cancer ( 17 ) , osteosarcoma ( 17 ) , breast cancer ( 7 ) , lung cancer ( 5 , 7 ) , non-small cell lung cancer ( 7 ) , non-small cell lung adenocarcinoma ( 5 ) , neuroblastoma ( 6 ) , pancreatic ductal adenocarcinoma ( 4 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:
'pancreatic, ductal'-pancreas ( 4 ) , 'stem, embryonic' ( 18 ) , 293 (epithelial) ( 3 , 19 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 15 ) , 293 (epithelial) [AT1 (human), transfection] ( 14 ) , 293E (epithelial) ( 10 ) , A498 (renal) ( 16 ) , BT-20 (breast cell) ( 7 ) , BT-549 (breast cell) ( 7 ) , Calu 6 (pulmonary) ( 7 ) , Flp-In T-Rex-293 (epithelial) ( 8 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 8 ) , GM00200 (fibroblast) ( 20 ) , GM18366 (fibroblast) ( 21 , 22 ) , H2009 (pulmonary) ( 7 ) , H2077 (pulmonary) ( 7 ) , H2887 (pulmonary) ( 7 ) , H322M (pulmonary) ( 7 ) , HCC1359 (pulmonary) ( 7 ) , HCC1937 (breast cell) ( 7 ) , HCC2279 (pulmonary) ( 7 ) , HCC4006 (pulmonary) ( 7 ) , HCC827 (pulmonary) ( 7 ) , HeLa (cervical) ( 11 , 12 ) , HUES-9 ('stem, embryonic') ( 13 ) , LCLC-103H (pulmonary) ( 7 ) , LOU-NH91 (squamous) ( 7 ) , lung ( 5 ) , MCF-7 (breast cell) ( 7 ) , NB10 (neural crest) ( 6 ) , NCI-H1395 (pulmonary) ( 7 ) , NCI-H157 (pulmonary) ( 7 ) , NCI-H1648 (pulmonary) ( 7 ) , NCI-H1666 (pulmonary) ( 7 ) , NCI-H2030 (pulmonary) ( 7 ) , NCI-H2172 (pulmonary) ( 7 ) , NCI-H460 (pulmonary) ( 7 ) , NCI-H520 (squamous) ( 7 ) , NPC (neural crest) ( 6 ) , PC9 (pulmonary) ( 7 ) , U2OS (bone cell) ( 17 ) , WM239A (epidermal) ( 2 )

References 

1

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

2

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

3

Wang R, et al. (2014) Global discovery of high-NaCl-induced changes of protein phosphorylation. Am J Physiol Cell Physiol 307, C442-54
24965592   Curated Info

4

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

5

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

6

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

7

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

8

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

9

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

10

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

11

Zhou J (2011) CST Curation Set: 11709; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

12

Zhou J (2011) CST Curation Set: 11710; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (S*Q) Immunoaffinity Beads Cat#: 9884
Curated Info

13

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

14

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

15

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

16

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

17

Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32
20058876   Curated Info

18

Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13
19664994   Curated Info

19

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

20

Stokes M (2006) CST Curation Set: 1772; Year: 2006; Biosample/Treatment: cell line, GM00200/UV; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

21

Stokes M (2006) CST Curation Set: 1774; Year: 2006; Biosample/Treatment: cell line, GM18366/UV; Disease: Seckel syndrome; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

22

Stokes M (2006) CST Curation Set: 1775; Year: 2006; Biosample/Treatment: cell line, GM18366/UV; Disease: Seckel syndrome; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info